Sponsored Content
Intercell reports Phase II Study Results of its Vaccine Enhancement Patch for Pandemic Influenza
Intercell AG today announced the results of a Phase II clinical trial of its investigational Vaccine Enhancement Patch (VEP) system for avian H5N1 influenza.
Intercell reports Phase II Study Results of its Vaccine Enhancement Patch for Pandemic Influenza / Picture: © Intercell
Intercell AG (VSE: ICLL) today announced the results of a Phase II clinical trial of its investigational Vaccine Enhancement Patch (VEP) system for avian H5N1 influenza.
In this development program, Intercell is working under a contract with the U.S. Department of Health and Human Services (HHS) to develop a dose-sparing approach with potential for a single dose immunization…
or Log In
Fast News Search